Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/19/2005WO2005044269A1 Cytokine inhibitory drugs for treatment of macular degeneration
05/19/2005WO2005044268A1 Preparation of pharmaceutical salts of [1, 4] - bipiperidine
05/19/2005WO2005044264A1 Ccr-2 antagonist salt
05/19/2005WO2005044263A1 Substituted 4-aryloxy and 4-arylsulfanyl-phenyl-2-aminothiazoles as inhibitors of cell proliferation
05/19/2005WO2005044262A1 Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
05/19/2005WO2005044261A1 Melatonin analogue prodrugs
05/19/2005WO2005044260A1 Use of crth2 antagonist compounds in therapy
05/19/2005WO2005044259A1 Composition and method for treating macular degeneration
05/19/2005WO2005044258A1 Simvastatin formulations and methods of making same
05/19/2005WO2005044257A1 Discodermolide compositions
05/19/2005WO2005044255A1 Stabilized pharmaceutical compositions
05/19/2005WO2005044254A1 Salts of pharmacologically active compounds
05/19/2005WO2005044253A1 Phenylpropanoic derivatives and compositions containing same, which stimulate libido and the associated physiological mechanisms
05/19/2005WO2005044252A1 Pump systems including injectable gabapentin compositions
05/19/2005WO2005044251A2 Methods of lowering lipid levels in a mammal
05/19/2005WO2005044250A1 Use of sulfonamide compounds for the treatment of diabetes and/or obesity
05/19/2005WO2005044249A1 Enos transcription enhancers for use in the cell therapy of ischemic heart diseases
05/19/2005WO2005044248A1 Use of proglumide and tramadol in the treatment of pain
05/19/2005WO2005044247A1 Pharmaceutical composition containing guaiacol derivatives and syringol derivatives extracted from natural plant vinegar
05/19/2005WO2005044246A2 Controlled release analgesic suspensions
05/19/2005WO2005044245A1 USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS
05/19/2005WO2005044244A2 Use of mrp4-inhibitors for the treatment and/or prophylaxis of cardiovascular diseases
05/19/2005WO2005044243A2 Transdermal analgesic systems having reduced abuse potential
05/19/2005WO2005044240A2 Stable lansoprazole formulation
05/19/2005WO2005044238A1 Modified release solid dosage form of amphetamine salts
05/19/2005WO2005044237A1 Pharmaceutical composition having a cationic excipient
05/19/2005WO2005044233A1 Formulations of n-oxide prodrugs of local anesthetics for the treatment of pulmonary inflammation associated with asthma, brochitis, and copd
05/19/2005WO2005044231A1 Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use
05/19/2005WO2005044230A2 Controlled release analgesic suspensions
05/19/2005WO2005044228A2 Compositions comprising cyclohexylamines and aminoadamantanes
05/19/2005WO2005044227A1 Topical pharmaceutical compositions
05/19/2005WO2005044225A2 Process for production of essentially solvent-free small particles
05/19/2005WO2005044223A1 Chewable tablet
05/19/2005WO2005044222A2 Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
05/19/2005WO2005044203A1 Vegetable substitute for lanolin
05/19/2005WO2005044201A2 Ph sensitive prodrugs of 2,6-diisopropylphenol
05/19/2005WO2005044200A2 Methods and compositions for treating mcp-1 related pathologies
05/19/2005WO2005044199A2 Combination of proton pump inhibitor and sleep aid
05/19/2005WO2005044198A2 Process and formulation containing epothilones and analogs thereof
05/19/2005WO2005044195A2 Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/19/2005WO2005044194A2 TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
05/19/2005WO2005044192A2 Triazole compounds and uses related thereto
05/19/2005WO2005044191A2 Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
05/19/2005WO2005044190A2 Compositions and methods for treatment of nervous system disorders
05/19/2005WO2005044182A2 Compositions of botanical extracts for cancer therapy
05/19/2005WO2005044180A2 Methods of reducing risk of infection from pathogens
05/19/2005WO2005044178A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
05/19/2005WO2005044176A2 Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
05/19/2005WO2005044175A2 Desensitization of complement activation using monocyte/macrophage inhibitory compounds
05/19/2005WO2005044130A1 Pdk-1/akt signaling inhibitors
05/19/2005WO2005044093A2 Delta-9- the treatment of multiple sclerosis
05/19/2005WO2005043971A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
05/19/2005WO2005035500A3 Therapeutic agents useful for treating pain
05/19/2005WO2005032560A3 Biological action of optically active isomers of digoxin
05/19/2005WO2005030140A3 C-met modulators and methods of use
05/19/2005WO2005030128A3 Pyrazole modulators of metabotropic glutamate receptors
05/19/2005WO2005027848A3 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
05/19/2005WO2005025583A3 Tlr7 ligands for the treatment of hepatitis c
05/19/2005WO2005025520A3 Chitosan spinning method, device therefor, and resulting chitosan yarn, and uses thereof
05/19/2005WO2005025517A9 Animal model for protease activity and liver damage
05/19/2005WO2005025501A3 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer
05/19/2005WO2005024025A8 Polyene polyketides and methods of production
05/19/2005WO2005023185A3 Pharmaceutical compositions and method of using levodopa and carbidopa
05/19/2005WO2005021496A3 Synthesis of derivatives of ginkgolide c
05/19/2005WO2005020968A3 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
05/19/2005WO2005020917A3 Ophthalmic compositions for treating ocular hypertension
05/19/2005WO2005020879A3 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
05/19/2005WO2005020862A8 Crosslinking reagent for treating vertebral disc disorders
05/19/2005WO2005019191A3 1, 1-dioxido-4h-1,2,4-benzothiadiazine derivate und verwandte verbindungen als inhibitoren der hcv polymerase zur behandlung von hepatitis c
05/19/2005WO2005018545A3 Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
05/19/2005WO2005018542A3 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
05/19/2005WO2005016228A3 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders
05/19/2005WO2005014576A8 Isoquinolinone derivative, process for producing the same and use thereof
05/19/2005WO2005013900A3 Method and composition for treating peridontal disease
05/19/2005WO2005012233A8 Meldonium salts, method of their preparation and pharmaceutical composition on their basis
05/19/2005WO2005011658A3 Chroman-derivated anti-androgens for treatment of androgen-mediated disorders
05/19/2005WO2005011614A8 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
05/19/2005WO2005011613A8 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
05/19/2005WO2005009410A3 Pharmaceutical compositions having a swellable coating
05/19/2005WO2005009346A3 Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
05/19/2005WO2005000211A3 Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
05/19/2005WO2004108083A3 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis
05/19/2005WO2004106492A3 Bicyclicpyrimidones and their use to treat diseases
05/19/2005WO2004106378A3 Method of treating corneal transplant rejection by using vegf antagonists
05/19/2005WO2004105701B1 Compositions and methods for symptomatic relief
05/19/2005WO2004100884A3 Oral care methods and products
05/19/2005WO2004092123A3 Inhibitors of fungal invasion
05/19/2005WO2004091531A3 Methods and devices for epithelial protection during photodynamic therapy
05/19/2005WO2004091529B1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
05/19/2005WO2004080409A3 Use of multivalent glycodendrimers to inhibit the activity of human immunodeficiency virus
05/19/2005WO2004078145B1 Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis
05/19/2005WO2004075846A3 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
05/19/2005WO2004072094A3 Hmgb1 modulator binding domain
05/19/2005WO2004069201A3 Compounds useful in coating stents to prevent and treat stenosis and restenosis
05/19/2005WO2004066934A3 Spermicidal and/or antifungal composition and methods of using the same
05/19/2005WO2004064719A3 Synergistic compositions and methods for potentiating anti-oxidative activity
05/19/2005WO2004064718A3 Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
05/19/2005WO2004062626A3 Composition and method for treating age-related disorders
05/19/2005WO2004052292A3 Histone deacetylase inhibitor enhancement of trail-induced apoptosis
05/19/2005WO2004050645A8 Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
1 ... 4683 4684 4685 4686 4687 4688 4689 4690 4691 4692 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 ... 7860